Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post hoc subgroup analysis from ECZTRA 7 trial

Main Article Content

Jan Gutermuth
Andrew Pink
Margitta Worm
Lise Soldbro
Thomas Mark
Joshua Corriveau
Christian Bjeeregard Oland
Stephan Weidinger

Keywords

tralokinumab, atopic dermatitis, efficacy, safety, dupilumab

Abstract

N/A

References

1. Weidinger S, Novak N. Lancet. 2016;387:1109–22;

2. Eckert L, et al. J Am Acad Dermatol. 2017;77:274–9.e273;

3. Silverberg JI, et al. Ann
Allergy Asthma Immunol. 2018;121:340–7;

4. Dalgard FJ, et al. J Invest Dermatol. 2015;135:984–91;

5. Bieber T. Allergy. 2020;75:54–62;

6. Tsoi LC, et al. J Invest Dermatol. 2019;139:1480–9;

7. Popovic B, et al. J Mol Biol. 2017;429:208–19;

8. Simpson et al. Safety of specifically targeting interleukin 13 with tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomised, doubleblind, placebo-controlled Phase 3 and Phase 2 trials. Poster presented at: 29th EADV Congress; 29-31 October 2020; Virtual.

Most read articles by the same author(s)

1 2 > >>